Online inquiry

IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12982MR)

This product GTTS-WQ12982MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12982MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9371MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ44MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 2857916
GTTS-WQ10121MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LAG-525
GTTS-WQ1026MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ7031MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ12852MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ7454MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ3063MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW